Recall of Human Rabies Immunoglobulin by Bio Products Laboratory Limited
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin due to a stability failure and reduced potency.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on March 30, 2026 and geographically references National. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly MHRA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized MHRA medicine alert is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, mhra, Medicine) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin following a stability failure, which has resulted in a reduction in potency of the product.
Which Products Are Affected
The affected product is Human Rabies Immunoglobulin 500IU solution for Injection from one specific batch, identified as EL(26)A/18. No model numbers, UPCs, quantities beyond one batch, or date ranges are specified in the alert.
What You Should Do
Consumers should stop using the affected batch and contact Bio Products Laboratory Limited for further instructions, as per the recall notice.
Why This Matters
This recall is significant because the reduced potency could compromise the effectiveness of the immunoglobulin in providing protection against rabies, potentially posing a serious health risk.
Source
This information is from the MHRA alert at https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bio-products-laboratory-limited-rabies-human-normal-immunoglobulin-500iu-solution-for-injection-el-26-a-slash-18.
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Frequently Asked Questions
Common questions about this MHRA medicine alert.